B Cell Lymphoma

B cell lymphoma is a blood cancer that develops from abnormal B cells. It accounts for 85% of all Non-Hodgkin lymphomas (NHLs), the sixth most common cancer in the United States.

B cells are specialized immune cells that are normally activated during an infection. These cells produce antibodies to fight the infection and die when the infection has been eliminated. Genetic changes within B cells can disrupt cellular signaling mechanisms, resulting in cancer.

An enzyme called Bruton’s tyrosine kinase (BTK) is critical in the replication and survival of B cells. Therefore, a therapy that blocks BTK has the potential to treat patients with B cell lymphoma by preventing B cells from dividing.


For more information, please visit:

For detailed information about completed and ongoing clinical studies for Abivertinib (AC0010), ACEA’s dual EGFR/BTK inhibitor, please visit clinicaltrials.gov.